Rentschler Biopharma Nukleus Building Laupheim

Your reliable CDMO partner

At Rentschler Biopharma, reliability you can trust is more than a promise—it's our commitment. As a global leader in Contract Development and Manufacturing Organization (CDMO) services for biopharmaceuticals, including advanced therapies, we take pride in our contributions to nearly 25% of FDA-approved biopharmaceuticals in 2023.

Our services

We offer full-service solutions for bioprocess development and manufacturing of high-quality biopharmaceuticals

Fueled by 50 years of experience in biopharmaceutical manufacturing, we lead the charge in empowering tomorrow's therapies today. Our international state-of-the-art facilities and expert solutions for the most complex biopharmaceuticals ensure excellence at every stage of your product's journey—from concept to market. Our strength lies in our experience with highly complex molecules. Discover how we can support your project. 

Our Track Record

With more than 50 years of industry experience, we at Rentschler Biopharma are highly qualified experts in the field of biopharmaceuticals. We share your passion for innovation and excellence and set standards in the biopharmaceutical industry.

> 130


Find out how we are helping to shape the future of biopharmaceuticals. Visit us at the leading industry trade fairs and get to know our team personally. Our news section informs you about the latest developments at our company.

Learn more

Thursday, July 11, 2024

Rentschler Biopharma Announces New State-of-the-Art Production Line in Massachusetts is Fully Operational

Rentschler Biopharma news after seven years of accelerated growth Dr. Frank Mathias to return to the Supervisory Board
Tuesday, June 11, 2024

Interview: Why instrument manufacturers and users must work together to meet future challenges in biopharmaceutical analysis

Friday, May 31, 2024

Rentschler Biopharma at Gene Therapy Development 2024

Rentschler Biopharma News Patrick Meyer appointed as Global Head BD Sales and Alliance Management
Tuesday, May 28, 2024

Rentschler Biopharma Appoints Patrick Meyer as Global Head BD Sales and Alliance Management

Wednesday, May 8, 2024

Playbook: Rethinking the Client-CDMO Relationship

Thursday, May 2, 2024

Rentschler Biopharma Appoints Patrick Cushing as VP Operations for U.S. Subsidiary

Rentschler Biopharma news after seven years of accelerated growth Dr. Frank Mathias to return to the Supervisory Board
Tuesday, April 30, 2024

Rentschler Biopharma at BIO International Convention San Diego 2024

Monday, April 29, 2024

Creative Disruption Forum on Cell & Gene Therapies: Making your company more investable

Regulatory compliance is particularly important for US and EU in clinical and commercial stage. Rentschler Biopharma has the knowledge to get into local markets quickly and risk-free.

— Director of a Biopharma company


As an independent family-owned company, Rentschler Biopharma employs approximately 1,400 people at its headquarters in Laupheim, Germany and a second site in Milford, MA, USA. A third site based in Stevenage, UK, specializes in cell and gene therapies. What unites us is our passion for what we do.

Our Job Openings

Rentschler Biopharma CDMO become part of the team

Get in Touch

Contact us now to discuss your needs and find solutions together.

*Required Fields